Cymru Marketing Journal - (CMJUK) - Online Business Journal & Digital Marketing Agency. Business News, Directory, SEO, Social Media Management, Advertising, Reviews, Forum, Market Research, Content Writing & Website Design. Thinking Local, Acting Global.

Day: 13 March 2023

Gene Therapy Start-Up Kriya Therapeutics

Gene Therapy Start-Up Kriya Therapeutics

Country: USA | Funding: $450.5M
Kriya Therapeutics is a next-generation gene therapy company focused on designing and developing transformative new treatments.

Kriya Therapeutics – Unleashing the Power of Gene Therapy

Who Are Kriya Therapeutics

Kriya Therapeutics is a start-up company focused on developing transformative gene therapies for the treatment of a wide range of genetic diseases. The company was founded in 2018 by Dr. Shankar Ramaswamy, Dr. Eric Kelsic, and Dr. Indu Ramachandran, all of whom have extensive experience in the field of gene therapy.

Kriya Therapeutics is headquartered in San Francisco, California, and has a team of world-class scientists, researchers, and business professionals working together to advance gene therapies that have the potential to cure genetic diseases that were previously considered untreatable.

The company’s approach is based on the use of adeno-associated virus (AAV) vectors to deliver therapeutic genes to the cells of patients. AAV vectors have been extensively studied and are considered safe and effective for gene therapy applications. Kriya Therapeutics is developing novel AAV vectors that have improved transduction efficiency and specificity, which allows for the targeted delivery of therapeutic genes to specific tissues and organs.

Kriya Therapeutics has a pipeline of gene therapies that are in various stages of development, including programs for the treatment of rare genetic diseases such as hemophilia, sickle cell disease, and lysosomal storage disorders. The company’s lead program is KRT-181, a gene therapy for the treatment of hemophilia B, which is currently in preclinical development.

Hemophilia is a genetic disorder that affects the blood’s ability to clot, which can lead to excessive bleeding and other complications. There are currently no cures for hemophilia, and patients require frequent infusions of clotting factors to prevent bleeding episodes. Kriya Therapeutics’ gene therapy for hemophilia B has the potential to provide a one-time cure for the disease, eliminating the need for frequent infusions and improving patients’ quality of life.

Kriya Therapeutics has also partnered with academic institutions and other companies to advance gene therapies for a range of diseases. The company has partnerships with the University of Pennsylvania and the Children’s Hospital of Philadelphia to develop gene therapies for lysosomal storage disorders, and with the University of California, San Francisco, to develop gene therapies for sickle cell disease.

In addition to its scientific and clinical work, Kriya Therapeutics is committed to building a diverse and inclusive company culture. The company has implemented policies and practices to promote diversity and inclusivity, including bias training for all employees and a diversity and inclusion council that provides recommendations for company-wide initiatives.

Kriya Therapeutics is a promising start-up that is poised to make significant contributions to the field of gene therapy. The company’s innovative approach to developing gene therapies has the potential to transform the lives of patients with genetic diseases, and its commitment to diversity and inclusivity reflects a forward-thinking and socially responsible approach to business. As Kriya Therapeutics continues to advance its pipeline of gene therapies, it will undoubtedly attract attention from investors, partners, and patients alike.

How do Kriya Therapeutics Market Themselves

Kriya Therapeutics markets itself through a variety of channels, including scientific conferences, social media, and its website.

Scientific conferences provide an opportunity for Kriya Therapeutics to showcase its research and development efforts to a broad audience of scientists, researchers, and investors. The company regularly presents at scientific conferences and publishes scientific papers in peer-reviewed journals to establish credibility and demonstrate its expertise in the field of gene therapy.

Kriya Therapeutics also utilizes social media to promote its company and its mission. They maintain active profiles on platforms such as LinkedIn and Twitter, where they share news about their research and development efforts, company updates, and job opportunities. By engaging with their followers and providing regular updates, Kriya Therapeutics aims to build a community of supporters and advocates for their gene therapy programs.

Finally, Kriya Therapeutics’ website serves as a hub for information about the company and its pipeline of gene therapies. The website features detailed descriptions of the company’s programs, team members, and partnerships, as well as press releases and news articles about the company’s progress. The website also provides a platform for potential investors and partners to learn more about Kriya Therapeutics and its approach to developing gene therapies.

Overall, Kriya Therapeutics markets itself by establishing its credibility through scientific publications and conference presentations, building a community of supporters through social media engagement, and providing detailed information about its company and pipeline on its website. By utilizing these various channels, Kriya Therapeutics aims to raise awareness of its gene therapy programs and attract the interest of potential investors, partners, and patients.

ADVERTISEMENT

If you found this article insightful and need similar content for your site please contact us using the button below:

Cymru Marketing Banner AD
CGTAI (www.ctgai.com) Logo

#kriyatherapeutics #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

Gene Therapy Start-Up Synthego

Gene Therapy Start-Up Synthego

Country: USA | Funding: $459.7M
Synthego is a provider of synthetic RNA solutions for CRISPR Genome Engineering.

Synthego | Engineered Cells and CRISPR Kits | Genome Engineering

Who Are Synthego

Synthego is a biotech start-up company based in California, USA, that specializes in developing gene editing tools and technologies. The company was founded in 2012 by brothers Paul and Michael Dabrowski, who have backgrounds in molecular biology and biochemistry.

The company’s mission is to accelerate the pace of genetic research and discovery by making gene editing technology more accessible and affordable to scientists and researchers. They have developed a platform called CRISPR, which is a powerful tool for editing and modifying genes.

CRISPR technology has revolutionized the field of genetic engineering, making it easier, faster, and more precise to modify genes. This technology has the potential to revolutionize medicine, agriculture, and other fields by allowing scientists to modify genetic material with unprecedented precision and efficiency.

Synthego has developed a suite of CRISPR tools, including guide RNA design, gene synthesis, and cell engineering, that enable researchers to edit genes with greater precision and accuracy. They have also developed an online platform that allows scientists to design and order custom CRISPR kits, which can be delivered to their laboratory in a matter of days.

The company has been successful in securing funding from a range of investors, including Andreessen Horowitz, Menlo Ventures, and 8VC. In 2021, they raised $110 million in a Series C funding round, bringing their total funding to over $240 million.

One of the key factors driving Synthego’s success is its commitment to innovation and research. They have invested heavily in research and development to improve the efficiency and accuracy of their CRISPR tools. They have also formed partnerships with leading academic and research institutions to collaborate on cutting-edge genetic research.

Synthego’s technology has been used by a wide range of researchers and scientists, including those working in medicine, agriculture, and biotechnology. Some of the applications of their technology include developing new therapies for genetic diseases, creating genetically modified crops that are resistant to pests and diseases, and engineering cells for use in cell therapies and regenerative medicine.

Synthego is a biotech start-up that is at the forefront of the gene editing revolution. Their commitment to innovation and research has enabled them to develop powerful CRISPR tools that are accessible and affordable to researchers worldwide. Their technology has the potential to revolutionize the fields of medicine, agriculture, and biotechnology, and we can expect to see many more exciting developments from this company in the future.

How Does Synthego Market Themselves

Synthego markets its business through a combination of digital and traditional marketing strategies. Here are a few ways they promote their brand:

  1. Social media: Synthego is active on social media platforms such as LinkedIn, Twitter, and Facebook. They use these platforms to share news, articles, and scientific papers related to their business and products. They also engage with their followers by responding to comments and questions.
  2. Webinars and events: Synthego hosts webinars and attends industry events to educate and engage with its target audience. They often partner with other companies or institutions to share their knowledge and showcase their products.
  3. Email marketing: Synthego sends out newsletters and email campaigns to its subscribers, which often include updates on new products, features, or collaborations. They also share scientific papers and articles related to gene editing and CRISPR technology.
  4. Content marketing: Synthego has a blog on its website where they publish articles related to its products, technology, and industry news. They also create educational resources such as guides and e-books that are available for download on their website.
  5. Search engine optimization (SEO): Synthego uses SEO strategies to improve its visibility and ranking on search engines. This includes optimizing their website content with relevant keywords and creating backlinks from reputable websites.

Overall, Synthego’s marketing strategy focuses on providing value to its target audience by sharing knowledge, educational resources, and innovative products. They use a mix of digital and traditional marketing strategies to reach and engage with their customers and partners.

ADVERTISEMENT

If you found this article insightful and would like similar content written for your business, just drop us a line using the button below:

Cymru Marketing Banner AD
CGTAI (www.ctgai.com) Logo

#synthego #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

Gene Therapy Start-Up Generation Bio

Gene Therapy Start-Up Generation Bio

Country: USA | Funding: $460.4M
Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people unaffected by inherited diseases. The company’s therapies are based on its proprietary GeneWave technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and sustain impact over a lifetime.

Home – Generation Bio

Who Are Generation Bio?

Gene therapy is a rapidly evolving field that aims to treat and cure genetic diseases by modifying a patient’s genes. The development of gene therapies is a complex and challenging process, but recent advances in technology and scientific understanding have made this field more promising than ever before. One company that is making significant strides in the field of gene therapy is Generation Bio.

Generation Bio is a Cambridge-based biotech start-up that was founded in 2016. The company’s mission is to develop breakthrough gene therapies that can address a broad range of genetic diseases. The team at Generation Bio is made up of experts in gene therapy, genetics, and molecular biology, and they are focused on developing innovative solutions to some of the most challenging medical conditions.

One of the key differentiators of Generation Bio is their proprietary technology platform called “closed-ended DNA” (ceDNA). This technology allows the company to deliver large and complex genes directly into a patient’s cells without triggering an immune response. This is a significant advantage over traditional gene therapy approaches that rely on viral vectors to deliver genes, which can cause an immune response and limit the effectiveness of the therapy.

Generation Bio’s ceDNA technology also enables the company to target specific tissues in the body, which is critical for treating genetic diseases that affect a particular organ or tissue. This precision targeting can improve the safety and efficacy of gene therapies and reduce the risk of side effects.

The company’s lead program is focused on developing gene therapy for hemophilia, a genetic disorder that affects the body’s ability to form blood clots. The current standard of care for hemophilia is regular infusions of clotting factor proteins, which can be costly and inconvenient for patients. Generation Bio’s gene therapy aims to provide a long-lasting solution by delivering the clotting factor gene directly into a patient’s liver cells.

In addition to its hemophilia program, Generation Bio is also working on gene therapies for other genetic diseases, including phenylketonuria (PKU), a rare metabolic disorder that can cause intellectual disability and other serious health problems. The company is also exploring gene therapies for rare genetic diseases that affect the liver, lung, and muscle tissues.

Generation Bio has already attracted significant investment from leading biotech companies and venture capital firms, including Takeda Pharmaceuticals, Atlas Venture, and Fidelity Management & Research Company. The company raised $110 million in its initial public offering (IPO) in June 2020, which will help fund its ongoing research and development efforts.

Overall, Generation Bio is an exciting new player in the field of gene therapy, with a promising technology platform and a strong pipeline of programs targeting a range of genetic diseases. With continued investment and scientific progress, gene therapy has the potential to transform the lives of millions of patients around the world, and companies like Generation Bio are at the forefront of this exciting new field.

How Does Generation Bio Market it’s business?

As a biotech startup focused on developing gene therapies, Generation Bio primarily markets its business to potential investors, strategic partners, and the scientific community.

Generation Bio has a strong online presence, with an informative website that highlights its technology platform, the pipeline of programs, and the leadership team. The website also provides updates on the company’s progress and recent news releases. The company actively engages with its followers on social media platforms such as Twitter, LinkedIn, and Facebook to share updates and interact with potential partners and investors.

Generation Bio also attends industry conferences and events to showcase its technology and pipeline of programs. These events provide opportunities for the company to network with potential investors, strategic partners, and key opinion leaders in the scientific community.

In addition, Generation Bio has established collaborations with other biotech companies and academic institutions to advance their gene therapy programs. These collaborations provide a platform for the company to showcase its technology and expertise, and to build relationships with potential partners.

Overall, Generation Bio markets its business through a variety of channels, including its online presence, participation in industry events, collaborations, and engagement with potential partners and investors. As a relatively new player in the gene therapy space, the company is focused on building awareness and establishing itself as a leader in the field through strategic marketing and communications efforts.

ADVERTISEMENT

If you found this article insightful and would like similar content written for your business, just drop us a line using the button below:

Cymru Marketing Banner AD
CGTAI (www.ctgai.com) Logo

#gererationbio #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

Gene Therapy Start-Ups Bluebird Bio

Gene Therapy Start-Ups Bluebird Bio

Country: USA | Funding: $484M
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.

bluebird bio | Pioneering Gene Therapies | Recode for Life

Who Are Bluebird Bio

Gene therapy is a revolutionary approach in the field of medicine that has the potential to cure genetic disorders by replacing, deleting, or repairing defective genes. One of the key players in the gene therapy industry is Bluebird Bio, a biotechnology company founded in 1992 that specializes in developing gene therapies for rare genetic diseases.

Bluebird Bio is a leading gene therapy company that has been at the forefront of developing transformative gene therapies for rare genetic diseases. The company’s focus on rare diseases is driven by the fact that many of these diseases have no existing treatments, leaving patients with few options for managing their conditions.

The company’s first gene therapy product, called Zynteglo, was approved by the European Medicines Agency (EMA) in 2019. Zynteglo is a treatment for beta-thalassemia, a rare blood disorder that results in the production of abnormal hemoglobin. The therapy involves inserting a functional copy of the beta-globin gene into the patient’s own stem cells, which are then transplanted back into the patient’s body. The therapy has been shown to eliminate the need for lifelong blood transfusions in some patients.

Bluebird Bio is also developing gene therapies for other rare diseases, including sickle cell disease, cerebral adrenoleukodystrophy (CALD), and multiple myeloma. The company’s sickle cell disease gene therapy, called LentiGlobin, is currently in clinical trials and has shown promising results in early studies. The therapy involves inserting a functional copy of the beta-globin gene into the patient’s own stem cells, which are then transplanted back into the patient’s body. The therapy has been shown to increase the production of healthy hemoglobin in patients, reducing the frequency of painful sickle cell crises.

In addition to its work on gene therapies, Bluebird Bio is also focused on developing innovative gene editing technologies. The company’s gene editing platform, called TALENs, uses custom-designed enzymes to precisely target and modify specific genes in the human genome. The technology has the potential to be used to treat a wide range of genetic diseases, including inherited disorders and certain types of cancer.

Bluebird Bio has been successful in securing significant funding to support its research and development efforts. The company has raised over $2 billion in funding from investors, including venture capital firms, strategic partners, and public markets. In 2018, the company entered into a strategic partnership with Regeneron Pharmaceuticals to develop gene therapies for genetic eye diseases.

While Bluebird Bio has made significant progress in the development of gene therapies, the field of gene therapy is still in its early stages, and there are many challenges that need to be overcome before these therapies can become widely available. These challenges include developing safe and effective delivery methods, optimizing dosing regimens, and addressing the high cost of gene therapies.

Bluebird Bio is a leader in the field of gene therapy, with a focus on developing transformative therapies for rare genetic diseases. The company’s successes in developing gene therapies for beta-thalassemia and sickle cell disease demonstrate the potential of gene therapy to provide life-changing treatments for patients with rare diseases. With its strong research and development capabilities, strategic partnerships, and significant funding, Bluebird Bio is well-positioned to continue making significant contributions to the field of gene therapy in the years to come.

How Does Bluebird Bio Market Their Business?

Bluebird Bio markets its business by primarily focusing on its innovative and transformative gene therapy products and technologies. The company employs various marketing strategies to raise awareness about its brand and products, build relationships with key stakeholders, and reach its target audience.

One of the key marketing strategies employed by Bluebird Bio is thought leadership. The company positions itself as a leader in the field of gene therapy by regularly publishing articles, presenting at scientific conferences, and participating in industry events. This approach helps to establish Bluebird Bio as a trusted and authoritative voice in the gene therapy space, which can help to attract investors, partners, and potential customers.

Bluebird Bio also uses content marketing to educate and engage its target audience. The company maintains an active blog and social media presence, where it shares updates on its research and development activities, highlights patient stories, and provides insights into the latest developments in the gene therapy field. By creating informative and engaging content, Bluebird Bio can attract and retain the attention of its target audience, which can help to build brand awareness and loyalty over time.

Another key marketing strategy employed by Bluebird Bio is strategic partnerships. The company has established partnerships with a variety of organizations, including academic institutions, pharmaceutical companies, and patient advocacy groups. These partnerships help to amplify Bluebird Bio’s message, expand its reach, and provide access to new resources and expertise. By working collaboratively with other organizations, Bluebird Bio can leverage the strengths of its partners to achieve its goals more efficiently and effectively.

Finally, Bluebird Bio uses traditional marketing channels such as advertising and public relations to promote its brand and products. The company may run targeted advertising campaigns in scientific journals or other industry publications to reach its target audience, or it may engage in media relations activities to secure coverage in mainstream media outlets. These activities help to increase the visibility of Bluebird Bio and its products, which can ultimately help to drive demand and support the company’s growth objectives.

In summary, Bluebird Bio markets its business by leveraging its innovative products and technologies, establishing thought leadership, engaging in content marketing, forming strategic partnerships, and using traditional marketing channels such as advertising and public relations. By using a variety of marketing strategies, Bluebird Bio can build brand awareness, attract customers and partners, and ultimately achieve its mission of developing life-changing gene therapies for patients with rare genetic diseases.

ADVERTISEMENT

If you found this article insightful and would like similar content written for your business, just drop us a line using the button below:

Cymru Marketing Banner AD
CGTAI (www.ctgai.com) Logo

#bluebirdbio #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

Gene Therapy Start-Up Sangamo Bio-Sciences

Gene Therapy Start-Up Sangamo Bio-Sciences

Country: USA | Funding: $522.1M
Sangamo is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various monogenic and infectious diseases with unmet medical needs.

Sangamo Therapeutics, Inc. | Pioneering Genetic Cures

Who Are Sangamo Bio-Sciences?

Sangamo Bio-Sciences is a leading biotechnology company specializing in gene therapy, gene editing, and cell therapy. The company is focused on developing innovative treatments for genetic diseases and disorders by utilizing its proprietary technologies, including zinc finger nucleases (ZFNs), TALE nucleases, and CRISPR/Cas9 gene editing systems.

Sangamo Bio-Sciences was founded in 1995 by Edward Lanphier, a biotechnology industry veteran. The company’s first breakthrough came in 1996 when it developed ZFN technology, a tool that can target specific genes in a patient’s DNA and modify them. This technology revolutionized the field of gene therapy and opened up new possibilities for treating genetic diseases.

Since then, the company has continued to advance its technology platform, expanding its focus to include cell therapy and gene editing. In 2015, Sangamo Bio-Sciences acquired TxCell, a French biotechnology company specializing in cell therapy, to broaden its expertise in the field. The acquisition enabled Sangamo Bio-Sciences to accelerate its efforts to develop CAR-T cell therapies, a promising new approach to cancer treatment.

Sangamo Bio-Sciences’ gene therapy approach involves introducing functional copies of a faulty gene into a patient’s cells to replace the defective ones. Gene editing, on the other hand, involves making precise changes to a patient’s DNA to correct or delete a faulty gene. The company’s cell therapy approach involves modifying a patient’s immune cells to target and destroy cancer cells.

One of Sangamo Bio-Sciences’ most promising therapies is SB-913, a gene therapy for Hunter syndrome, a rare genetic disorder that affects approximately 1 in 100,000 males. The therapy involves using a viral vector to introduce a functional copy of the gene that is missing or defective in patients with Hunter syndrome. The company has reported positive results from a Phase 1/2 clinical trial of SB-913, with patients showing sustained levels of the missing enzyme and a reduction in symptoms.

Sangamo Bio-Sciences has also made significant progress in developing gene editing therapies for a range of genetic diseases, including sickle cell disease, beta-thalassemia, and Huntington’s disease. The company’s proprietary In Vivo Protein Replacement Platform (IVPRP) enables the delivery of gene editing enzymes directly into a patient’s liver, allowing for precise editing of genes responsible for these diseases.

In addition to its proprietary technologies, Sangamo Bio-Sciences has also formed partnerships with other biotechnology companies and academic institutions to advance its research and development efforts. For example, the company has partnered with Pfizer to develop gene therapies for hemophilia, a genetic disorder that affects blood clotting.

Sangamo Bio-Sciences’ innovative approach to gene therapy, gene editing, and cell therapy has earned it a reputation as a leader in the field. The company has a strong pipeline of therapies in development and is well-positioned to bring innovative treatments to patients with genetic diseases and disorders. With continued investment in research and development, Sangamo Bio-Sciences is poised to make a significant impact on the field of gene therapy and revolutionize the treatment of genetic diseases.

How Does Sangamo Bio-Science Market Their Business?

Sangamo Bio-Sciences markets its business through a combination of traditional and modern marketing methods. Here are some ways the company promotes its products and services:

  1. Industry Conferences and Events: Sangamo Bio-Sciences attends and sponsors various conferences and events related to gene therapy, gene editing, and cell therapy. These events provide the company with the opportunity to showcase its technology and expertise, network with potential partners and customers, and stay up-to-date on the latest developments in the industry.
  2. Scientific Publications: Sangamo Bio-Sciences regularly publishes its research findings in scientific journals and presents at scientific conferences. This helps to establish the company as a thought leader in the field and promotes its technology to other researchers and potential partners.
  3. Digital Marketing: The company maintains an active website, social media profiles, and email newsletters to communicate with its customers, investors, and stakeholders. The website provides detailed information about the company’s technology, products, and services. Social media profiles are used to share news, research findings, and industry insights.
  4. Direct Sales and Partnerships: Sangamo Bio-Sciences has a dedicated sales team that markets its products and services directly to healthcare providers, researchers, and institutions. The company also partners with pharmaceutical companies, academic institutions, and government agencies to collaborate on research and development projects.
  5. Investor Relations: The company maintains an active investor relations program to communicate with its investors and potential investors. This includes regular earnings calls, presentations at investor conferences, and investor roadshows.

In summary, Sangamo Bio-Sciences markets its business through a variety of channels, including industry conferences, scientific publications, digital marketing, direct sales, partnerships, and investor relations. By leveraging these channels, the company is able to build its brand, showcase its technology, and attract new customers, partners, and investors.

ADVERTISEMENT

If you found this article insightful and need similar content for your site please contact us using the button below:

Cymru Marketing Banner AD

#SangamoBioSciences #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

Gene Therapy Start-Up Tessera Therapeutics

Gene Therapy Start-Up Tessera Therapeutics

Country: USA | Funding: $531.8M
Tessera Therapeutics is pioneering Gene Writing – a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source.

Tessera Therapeutics | A Flagship Pioneering Company

Who Are Tessera Therapeutics?

Gene therapy is a rapidly evolving field that aims to treat genetic disorders by introducing therapeutic genes into a patient’s cells. Tessera Therapeutics is a start-up that is at the forefront of this field, developing innovative gene editing and delivery technologies that have the potential to revolutionize the way we treat genetic diseases.

Founded in 2019, Tessera Therapeutics is a spin-out from the Broad Institute of MIT and Harvard, a world-renowned research institution that has made significant contributions to the field of genomics. The company is led by Chief Executive Officer Geoffrey von Maltzahn, a serial entrepreneur with a background in biotechnology and engineering.

Tessera’s approach to gene therapy is based on a novel technology called Gene Writing™, which is designed to precisely edit the genome to introduce therapeutic genes into specific cells or tissues. This technology involves the use of a programmable DNA-binding protein called a transcription activator-like effector (TALE), which can be customized to target specific sequences of DNA.

The Gene Writing™ technology is highly versatile, allowing Tessera to develop therapies for a wide range of genetic disorders, including those that are caused by single-gene mutations or more complex genetic changes. The company is currently focused on developing therapies for rare diseases, where there is a high unmet medical need and a limited number of treatment options.

Tessera’s Gene Writing™ technology is complemented by its proprietary platform for gene delivery, which is based on a class of viruses called adeno-associated viruses (AAVs). AAVs are naturally occurring viruses that are widely used in gene therapy because they are safe, non-pathogenic, and have the ability to infect a wide range of cell types.

Tessera has developed a suite of AAV vectors that are optimized for specific tissues or organs, allowing the company to target different parts of the body with precision. This platform has the potential to overcome some of the challenges associated with gene therapy, such as off-target effects, immune reactions, and limited tissue penetration.

One of the key advantages of Tessera’s approach is its ability to edit genes in vivo, meaning that the therapy can be delivered directly to the patient without the need for ex vivo manipulation of cells. This could greatly simplify the process of gene therapy and reduce the cost and complexity of treatment.

Tessera’s Gene Writing™ technology and AAV platform are still in the early stages of development, but the company has already made significant progress in bringing its therapies to the clinic. In December 2020, Tessera announced a collaboration with Biogen to develop gene therapies for neurological diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

The collaboration with Biogen provides Tessera with significant financial resources and expertise in clinical development and regulatory affairs, which will be critical for advancing its therapies through clinical trials and toward commercialization. Tessera also recently announced a $230 million Series B funding round, which will support the company’s continued growth and expansion.

In summary, Tessera Therapeutics is a promising start-up that is using innovative gene editing and delivery technologies to develop therapies for genetic diseases. Its Gene Writing™ technology and AAV platform have the potential to overcome some of the limitations of existing gene therapies and provide a new approach to treating rare diseases. With the support of Biogen and other investors, Tessera is well-positioned to advance its therapies through clinical development and towards commercialization, bringing hope to patients with genetic disorders.

How does Tessera Therapeutics Market their Business?

As a biotech startup, Tessera Therapeutics primarily markets its business to investors, potential partners, and the scientific community. The company’s marketing efforts focus on highlighting its innovative gene editing and delivery technologies, as well as its strong scientific team and partnerships.

Tessera’s website serves as a primary marketing tool, providing information about the company’s technology platform, the pipeline of therapies, and scientific publications. The website also features news and press releases highlighting the company’s latest developments, collaborations, and funding rounds.

In addition to its website, Tessera uses social media platforms, such as Twitter and LinkedIn, to share news and updates with a wider audience. The company also attends scientific conferences and events to showcase its technology and network with potential partners and investors.

One of Tessera’s most significant marketing efforts to date has been its collaboration with Biogen, a leading biopharmaceutical company. The partnership not only provides Tessera with significant financial resources but also increases the company’s visibility within the industry and demonstrates the potential of its technology.

Overall, Tessera’s marketing strategy is focused on building awareness and credibility within the scientific community and attracting investors and partners who share the company’s vision of using gene editing and delivery technologies to transform the treatment of genetic diseases.

ADVERTISEMENT

If you found this article insightful and need similar content for your site please contact us using the button below:

Cymru Marketing Banner AD
CGTAI (www.ctgai.com) Logo

#TesseraTherapeutics #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

Gene Therapy Start-Up Editas Medicine’s

Gene Therapy Start-Up Editas Medicine’s

Country: USA | Funding: $656.6M
Editas Medicine’s mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Editas Medicine

Who Are Editas Medicines?

Editas Medicine is a biotechnology company that specializes in gene editing technology. The company was founded in 2013 by a group of leading scientists in the field of gene editing, including Feng Zhang, George Church, and Jennifer Doudna. Since its inception, Editas Medicine has been at the forefront of the gene therapy revolution, developing innovative therapies that have the potential to cure a wide range of diseases.

Gene editing technology allows scientists to modify an organism’s DNA in a precise and targeted way. This technology has enormous potential for treating genetic diseases, such as cystic fibrosis, sickle cell anemia, and Huntington’s disease. Editas Medicine has developed a range of gene editing tools, including the CRISPR/Cas9 system, which is widely considered to be one of the most powerful and precise gene editing tools available.

One of the most exciting applications of gene editing technology is in the field of medicine. Editas Medicine is working on a range of therapies that have the potential to cure or treat genetic diseases. One such therapy is for Leber congenital amaurosis (LCA), a rare genetic disorder that causes blindness. Editas Medicine has developed a gene therapy that uses the CRISPR/Cas9 system to correct the mutation that causes LCA. The therapy has shown promising results in preclinical studies, and the company plans to begin clinical trials in the near future.

Editas Medicine is also developing gene therapies for other genetic diseases, including sickle cell anemia, beta-thalassemia, and Duchenne muscular dystrophy. These therapies have the potential to transform the lives of millions of people around the world who suffer from these diseases.

In addition to its work in gene therapy, Editas Medicine is also developing a range of other gene editing technologies. These include tools for agricultural applications, such as creating crops that are more resistant to pests and diseases, and for industrial applications, such as creating bacteria that can produce valuable chemicals and fuels.

Editas Medicine has attracted significant investment from some of the world’s leading biotech investors, including Google Ventures, Polaris Partners, and Third Rock Ventures. The company has also formed partnerships with leading pharmaceutical companies, such as Allergan and Juno Therapeutics, to develop new gene therapies.

Despite its successes, Editas Medicine has faced some challenges in its journey to becoming a leading player in the gene therapy field. In 2018, the company was embroiled in a legal dispute with the Broad Institute of MIT and Harvard over the ownership of the CRISPR/Cas9 gene editing technology. The dispute was eventually resolved in Editas Medicine’s favor, but it highlights the complex legal and ethical issues surrounding gene editing technology.

Overall, Editas Medicine is a pioneering company that is at the forefront of the gene therapy revolution. Its cutting-edge gene editing technology has the potential to cure or treat a wide range of genetic diseases, and its innovative approach to gene editing has the potential to transform agriculture, industry, and many other fields. With significant investment and strong partnerships, Editas Medicine is well-positioned to continue its success and make a significant impact on the world.

How does Editas Medicines Market Their Business?

As a biotechnology company specializing in gene editing technology, Editas Medicine employs a range of marketing strategies to promote its business and attract investment, partners, and potential customers. Here are some ways Editas Medicine markets its business:

  1. Online Presence: Editas Medicine has a strong online presence, with an informative and engaging website that showcases its gene editing technology, team, and progress. The website features detailed descriptions of the company’s therapies and technology, as well as news and updates about its latest developments. The company also uses social media platforms like Twitter and LinkedIn to share news and connect with its audience.
  2. Conferences and Events: Editas Medicine frequently participates in scientific and industry conferences and events, where its team members give talks and presentations on the company’s technology and progress. These events provide opportunities for networking, building relationships with potential partners and investors, and gaining exposure to a wider audience.
  3. Partnerships and Collaborations: Editas Medicine has formed partnerships with leading pharmaceutical companies, including Allergan and Juno Therapeutics, to develop new gene therapies. These partnerships help to raise the profile of the company and demonstrate its expertise in the field of gene editing.
  4. Media Coverage: Editas Medicine has received extensive media coverage in the scientific, business, and mainstream press. The company’s groundbreaking research and potential to cure genetic diseases have captured the attention of journalists and investors alike. This media coverage helps to raise awareness of the company and its mission.
  5. Thought Leadership: Editas Medicine’s team members frequently publish papers in scientific journals and participate in panel discussions and interviews. By sharing their expertise and insights, the team members demonstrate the company’s leadership in the field of gene editing and position themselves as thought leaders.

In summary, Editas Medicine employs a range of marketing strategies, including online presence, conferences and events, partnerships, media coverage, and thought leadership, to promote its business and position itself as a leader in the field of gene editing technology.

ADVERTISEMENT

If you found this article insightful and need similar content for your site please contact us using the button below:

Cymru Marketing Banner AD
CGTAI (www.ctgai.com) Logo

#EditasMedicines #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

Gene Therapy Start-Up Sana Biotechnology

Gene Therapy Start-Up Sana Biotechnology

Country: USA | Funding: $700M
Sana Biotechnology is a developer of engineered cells intended to be used as medicine for patients. It’s deploying a platform that can repair and control genes in cells or replace any cell in the body.

Home – Sana Biotechnology

Who Are Sana Biotechnology?

Gene therapy is a promising field that seeks to use genetic material to treat or cure various diseases. Sana Biotechnology is a biotech startup that was founded in 2018 to advance the development of gene therapies. The company is based in Seattle, Washington, and has raised over $700 million in funding to date.

Sana Biotechnology aims to develop genetic therapies that can target and treat a range of diseases, including cancer, neurological disorders, and rare genetic diseases. The company’s approach to gene therapy involves using modified viral vectors to deliver genetic material to specific cells in the body. This technology has the potential to provide long-lasting treatments that can correct genetic defects and restore normal cellular function.

One of Sana Biotechnology’s primary areas of focus is cancer. The company is developing gene therapies that can target cancer cells directly, without harming healthy cells. Sana’s approach involves using CAR-T cell therapy, which involves modifying the patient’s immune cells to recognize and attack cancer cells. The company is also developing therapies that can target specific mutations in cancer cells, which could lead to more personalized and effective treatments.

Sana Biotechnology is also developing gene therapies for neurological disorders, such as Alzheimer’s disease and Parkinson’s disease. The company’s approach involves using viral vectors to deliver genetic material to the brain, which can help to restore normal neuronal function. This technology has the potential to provide long-lasting treatments for these debilitating conditions.

In addition to cancer and neurological disorders, Sana Biotechnology is also working on gene therapies for rare genetic diseases. The company is using its expertise in viral vector technology to develop therapies that can correct genetic defects and restore normal cellular function. This could provide hope for patients who currently have few treatment options for their rare conditions.

Sana Biotechnology is still a relatively new company, but it has already made significant progress in the field of gene therapy. The company has assembled a team of experienced scientists and researchers who are dedicated to developing innovative therapies that can transform the lives of patients. With the backing of significant funding, Sana Biotechnology is well-positioned to continue advancing the development of gene therapies that can target a wide range of diseases.

Overall, Sana Biotechnology represents an exciting new player in the field of gene therapy. With its innovative technology and experienced team, the company has the potential to make significant contributions to the development of new treatments for cancer, neurological disorders, and rare genetic diseases. As research in this field continues to advance, Sana Biotechnology will be at the forefront of this exciting new frontier in medicine.

How does Sana Biotechnology Market Themselves?

As a relatively new biotech startup, Sana Biotechnology has been actively marketing itself in various ways to promote its mission and attract investors and partners. Here are a few ways that Sana Biotechnology has been marketing itself:

  1. Building a strong online presence: Sana Biotechnology has a website that provides detailed information about its technology, team, and research areas. The website also features news and press releases about the company, as well as job postings and events. The company has also created social media accounts on platforms like Twitter and LinkedIn, where they share updates and engage with their audience.
  2. Attending industry events: Sana Biotechnology has been attending various industry events and conferences to showcase its technology and connect with potential partners and investors. For example, the company participated in the JP Morgan Healthcare Conference in 2020, which is one of the largest healthcare conferences in the world.
  3. Partnering with other companies: Sana Biotechnology has formed partnerships with other companies in the biotech industry to further their research and development efforts. For example, in 2020, Sana Biotechnology announced a collaboration with Denali Therapeutics to develop gene therapies for neurological diseases.
  4. Issuing press releases: Sana Biotechnology regularly issues press releases to announce its latest developments and milestones. These press releases are distributed to various media outlets and can help raise awareness of the company’s technology and accomplishments.
  5. Hiring experienced professionals: Sana Biotechnology has been actively hiring experienced professionals in the biotech industry to join its team. By hiring top talent, the company is able to leverage the expertise of its employees to further its research and development efforts.

Overall, Sana Biotechnology has been marketing itself through a combination of online and offline efforts. By building a strong online presence, attending industry events, partnering with other companies, issuing press releases, and hiring experienced professionals, the company is positioning itself as a leading player in the field of gene therapy.

ADVERTISEMENT

If you found this article insightful and need similar content for your site please contact us using the button below:

Cymru Marketing Banner AD
CGTAI (www.ctgai.com) Logo

#SanaBiotechnology #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

Gene Therapy Start-Up Autolus

Gene Therapy Start-Up Autolus

Country: UK | Funding: $781.6M
Autolus utilizes advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of hematological malignancies and solid tumors.

Autolus – developing CAR T cell therapies for cancer patients

Who are Autolus and what do they do?

Autolus Bio-Technology is a biopharmaceutical company that specializes in the development of innovative gene therapies for the treatment of cancer. The company was founded in 2014 and is headquartered in London, United Kingdom.

The company’s primary focus is on the development of CAR-T cell therapies, which involve genetically modifying a patient’s own T cells to recognize and destroy cancer cells. Autolus Bio Technology’s proprietary technology platform allows for the creation of CAR-T cells with improved efficacy and safety profiles compared to traditional CAR-T therapies.

One of the company’s most advanced programs is AUTO1, a CD19-targeted CAR-T cell therapy for the treatment of B-cell malignancies. In clinical trials, AUTO1 has demonstrated high response rates and durable remissions in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and pediatric acute lymphoblastic leukemia (ALL).

Autolus Bio-Technology is also developing other CAR-T cell therapies, including AUTO2 for the treatment of multiple myeloma, AUTO3 for the treatment of DLBCL and pediatric ALL, and AUTO4 for the treatment of T cell lymphoma.

In addition to CAR-T cell therapies, Autolus Bio-Technology is also developing T cell receptor (TCR) therapies, which involve genetically modifying T cells to recognize cancer cells based on specific antigens. The company’s lead TCR therapy program is targeting solid tumors, including ovarian and lung cancers.

Autolus Bio-Technology has a strong pipeline of product candidates and a robust research and development program focused on the discovery of novel therapies for the treatment of cancer. The company has established partnerships with leading academic institutions and pharmaceutical companies to advance its research and development efforts.

Autolus Bio Technology’s mission is to develop innovative therapies that can transform the lives of patients with cancer. The company’s CAR-T cell and TCR therapies have the potential to revolutionize cancer treatment and offer new hope to patients who previously had limited treatment options.

Overall, Autolus Bio-Technology is a promising biopharmaceutical company with a strong focus on developing innovative gene therapies for the treatment of cancer. With a deep pipeline of product candidates and a commitment to advancing the field of gene therapy, Autolus Bio-Technology is well-positioned to make a significant impact in the fight against cancer.

How Does Autolus Market Their Business?

Autolus is a UK-based clinical-stage biopharmaceutical company that focuses on the development of next-generation, programmed T-cell therapies for the treatment of cancer. Their innovative approach to cancer treatment has garnered attention from investors and patients alike, and Autolus has become a leading player in the biotech industry. So how does Autolus market its business?

Autolus markets its business primarily through three channels: investor relations, media outreach, and patient advocacy.

Investor Relations:

As a publicly traded company, Autolus places a strong emphasis on investor relations. They regularly participate in investor conferences and events and maintain an active presence on social media platforms like Twitter and LinkedIn. Autolus also hosts quarterly earnings calls to update investors on their progress and financial performance. By maintaining a transparent and informative relationship with investors, Autolus is able to build trust and foster long-term relationships.

Media Outreach:

Autolus also places a strong emphasis on media outreach. They work with leading publications and journalists in the biotech industry to generate buzz and awareness around their innovative therapies. Autolus frequently publishes press releases and company updates to keep the media and the public informed about its progress. By maintaining an active and engaging presence in the media, Autolus is able to build a strong brand and establish itself as a thought leader in the industry.

Patient Advocacy:

Autolus recognizes that its work has the potential to make a profound impact on the lives of cancer patients. As such, they have placed a strong emphasis on patient advocacy. Autolus works with patient advocacy groups and non-profits to educate patients and their families about their therapies and the potential benefits they offer. By placing patients at the center of its mission, Autolus is able to build a strong community of supporters who are passionate about their work.

Conclusion

Autolus has built a strong marketing strategy that focuses on investor relations, media outreach, and patient advocacy. By establishing itself as a thought leader in the biotech industry and fostering strong relationships with investors and patients, Autolus has been able to generate buzz and excitement around its innovative therapies. As they continue to advance their pipeline and bring new therapies to market, Autolus will no doubt continue to be a major player in the biotech industry.

ADVERTISEMENT

If you found this article insightful and need similar content for your site please contact us using the button below:

Cymru Marketing Banner AD
CGTAI (www.ctgai.com) Logo

#autolus #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting

UK’s PM warns that Britain is ‘ready for conflict’ against Russia amid ‘growing international volatility’

UK’s PM warns that Britain is ‘ready for conflict’ against Russia amid ‘growing international volatility’

Sunak warns the UK is now ‘ready for conflict’ against Russia amid ‘growing international volatility’ – London Business News | Londonlovesbusiness.com

Wallace warns ‘war is coming’ as Putin to send apocalyptic Satan 2 nuclear capable missiles into combat – London Business News | Londonlovesbusiness.com

** Disclaimer** I have purposely turned my notifications off because of the impending catastrophe waiting to happen and the repercussions of my mental health having to worry, will Britain get through this? It was only because a client of mine in Serbia emailed me he is worried that I decided to have a look. According to the headline written by LLB Political Reporter (no name), he claims Sunak has warned Britain. For those that do not read national papers and perhaps do not have internet access, he has not done a good job of warning Britain. I understand putting this in mainstream media may cause a moral panic, but at least tell people to stock up on survival equipment and tinned food. Hopefully, we will not need any of this but it is better to be safe than sorry: 75 Emergency Supplies List You Should Always Stock at Home (morningchores.com)

Concerns

The Former Chancellor of the Exchequer, Rishi Sunak and now Prime Minister has warned that the United Kingdom is now “ready for conflict” against Russia amid “growing international volatility.” The warning comes as tensions between the two countries have been escalating in recent years, with Russia accused of various acts of aggression against the UK and its allies.

In a speech delivered at the annual Lord Mayor’s Banquet in London, Sunak said that the UK must be prepared to “act decisively” to protect its interests and those of its allies. He warned that “we cannot ignore the threat posed by Russia,” adding that “our adversaries are using a range of tactics to undermine our security and prosperity.”

Sunak’s remarks come as the UK has been increasingly vocal in its criticism of Russia’s actions on the world stage. In recent years, Russia has been accused of interfering in the 2016 US presidential election, carrying out cyberattacks against a number of countries, and violating the sovereignty of Ukraine.

The UK has also accused Russia of being behind the poisoning of former Russian spy Sergei Skripal and his daughter in Salisbury in 2018. The incident led to a major diplomatic row between the UK and Russia, with both countries expelling each other’s diplomats.

Sunak’s warning reflects growing concern among Western countries about Russia’s increasing assertiveness on the world stage. The country has been investing heavily in its military capabilities in recent years and has also been accused of using disinformation and propaganda to undermine Western democracies.

However, while the UK has been vocal in its criticism of Russia, it remains to be seen what concrete action it will take to counter the threat posed by the country. The UK has traditionally been a key player in NATO, the military alliance of Western countries, and has also maintained close ties with the United States.

It is possible that the UK will seek to take a more assertive stance against Russia in the coming years, particularly if tensions continue to escalate. However, any such action would need to be carefully calibrated to avoid a direct military confrontation, which could have catastrophic consequences for both countries and the wider world.

In the meantime, Sunak’s warning serves as a reminder of the growing tensions between the UK and Russia, and the need for Western countries to remain vigilant and prepared to act to protect the nation.

Do world leaders not care about killing people in war

War is an unfortunate reality that has existed for centuries, and with it comes the unfortunate reality of casualties. In modern times, war has evolved to become more lethal and devastating, resulting in the deaths of countless civilians and soldiers alike. Despite the tragic consequences of war, world leaders continue to engage in armed conflicts without much regard for the lives of those caught in the crossfire.

One of the reasons why world leaders seem to be indifferent to the loss of life in war is the dehumanization of the enemy. In most cases, leaders tend to depict the opposing side as evil and inhumane, making it easier to justify the use of force. This portrayal of the enemy as sub-human makes it easier for soldiers to kill without remorse and for civilians to support their country’s actions, even if it means the deaths of innocent people.

Another reason why world leaders seem to be apathetic towards the loss of life in war is the idea of “collateral damage.” Collateral damage refers to the unintentional harm caused to civilians or their property during military operations. While world leaders often express regret for civilian deaths, they tend to downplay the severity of the situation, arguing that the deaths were a regrettable but necessary consequence of war.

Moreover, the idea of national interest plays a significant role in justifying the use of force. Many world leaders argue that war is necessary

However, it is important to recognize that decisions regarding war and military action are often complex and involve a range of factors such as geopolitical interests, security concerns, and humanitarian considerations. While some leaders may believe that military action is necessary for the greater good, others may have different motives or be influenced by external pressures. Additionally, the impact of these decisions on innocent civilians is often a tragic consequence that cannot be overlooked. It is important for leaders to consider the consequences of their actions and make decisions that prioritize the safety and well-being of all individuals involved.

Further Reading

Ten nuclear warheads ‘switched off’ by nearby UFOs, investigators told – Mirror Online I believe this was a warning.

Pentagon Investigating UFOs That Possibly Turned Off Warheads (popularmechanics.com)

UFO switched off 10 nuclear warheads (msn.com)

UFO flying over military base switched off 10 nuclear warheads, investigators told – Daily Star

ALIENS LATEST: Nuclear WW3 between US and Russia ‘prevented by aliens’ | Weird | News | Express.co.uk

In the Event of a Nuclear Emergency:

Nuclear emergencies: information for the public – GOV.UK (www.gov.uk)

Emergency Alert Sound

Emergency alerts will sound sirens and warnings on mobile phones with national testing expected within weeks (msn.com)

Final Notes From The Editor

“I pray to God and to the Universe, that WWIII will not happen and that Britain will be safe”.

I am protecting my mental health by avoiding reading too much into this.

Obviously, stock up on necessities, there is no point in panic buying but do the odd shop from time to time and tick off the list of things you may need. 75 Emergency Supplies List You Should Always Stock at Home (morningchores.com)

There is no harm in being precautious!

If you find your mental health to be affected by the news just head over to our useful links page on our other site: www.disabledentrepreneur.uk

ADVERTISEMENT

If you found this article insightful and wish us to write similar content for you, just drop us a line.

Cymru Marketing Banner AD

#conflict #nato #sunak #rishisunak #britain #uk #nuclearstrike #nuclearbomb #russia #worldleaders #putin #ww3 #wwiii #war